Genprex Secures New Patent for Innovative Cancer Therapy
Genprex, Inc. (NASDAQ: GNPX), a pioneering clinical-stage gene therapy enterprise, has recently announced a significant milestone. The European Patent Office has expressed its intent to grant a patent focused on the use of Reqorsa® Gene Therapy along with PD-1 antibodies, specifically targeting the treatment of cancer.
Strengthening Intellectual Property Portfolio
This announcement highlights Genprex's commitment to enhancing its patent estate, which already encompasses multiple patents recognizing the synergy between REQORSA and immune checkpoint inhibitors. Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, shared, "We are pleased to continue bolstering our patent estate, which includes several patents for the use of REQORSA in combination with both PD-1 and PD-L1 antibodies across many markets. This new patent will further augment our intellectual property portfolio and enhance the protection surrounding REQORSA, safeguarding its application in targeted combination therapies."
Expanding to Global Markets
The forthcoming patent not only encompasses previously issued patents for REQORSA in conjunction with PD-1 antibodies but also extends its reach beyond territories like the U.S., Japan, Mexico, Russia, and Australia among others. This global focus allows Genprex to strategically position REQORSA within diverse international markets, offering patients potential new treatment avenues.
Clinical Potential of Reqorsa® Gene Therapy
REQORSA is strategically developed to work alongside established and effective cancer medications with the aim of treating lung cancer. Early studies have demonstrated REQORSA's compatibility with targeted therapies and immunotherapies, suggesting it could enhance current treatment protocols for patients fighting lung cancer and possibly extend to other types of cancer as well. The company believes that REQORSA's unique properties may provide an improved treatment option compared to existing therapies.
Lung Cancer Statistics and Future Projections
Lung cancer remains a critical public health issue in Europe, with Eurostat data showing nearly 250,000 fatalities due to lung cancer in 2021, accounting for around 20% of total cancer deaths. Moreover, lung cancer constituted approximately 11.9% of new cancer diagnoses in the EU-27, and projections estimate a 4.62 million new cases and 3.55 million deaths due to lung cancer globally by 2050 if current trends continue. This underscores the importance and urgency of developing more effective treatment options, such as those offered by Genprex.
About Genprex, Inc.
Genprex, Inc. is a trailblazer in clinical-stage gene therapies aimed at changing the lives of patients facing cancer and diabetes. The company specializes in delivering groundbreaking therapies through its innovative technologies that leverage disease-fighting genes. Through collaborations with premier institutions, Genprex is working towards advancing its pipeline of therapies to offer transformative treatment possibilities. Their approach employs a systemic, non-viral delivery system called Oncoprex®, which facilitates the delivery of gene-expressing plasmids using lipid-based nanoparticles. This process allows for a targeted attack on tumor cells, potentially revitalizing the body's ability to combat cancer.
The lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is currently under evaluation in two clinical trials focusing on treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). With designation as Fast Track by the FDA for both lung cancer programs and Orphan Drug Designation for SCLC, Genprex evinces a robust commitment to meeting the challenges presented by these debilitating conditions.
Investors and stakeholders are encouraged to stay updated on Genprex's developments by visiting the company's official website and subscribing to email alerts. Engagement through social media platforms is also available for continuous updates and industry news.
Frequently Asked Questions
What is the significance of the new patent granted to Genprex?
The new patent protects the use of Reqorsa® Gene Therapy in combination with PD-1 antibodies, enhancing Genprex's intellectual property portfolio and strategic position in cancer treatment.
How does Reqorsa® function in cancer therapy?
Reqorsa® is designed to work with existing cancer treatments, aiming to enhance their effectiveness through a unique gene therapy approach that targets tumor cells directly.
What types of cancer is Reqorsa® targeted towards?
Initially, Reqorsa® is being developed for lung cancer treatments, with potential applications for other types of cancer as research continues.
How does Genprex's approach differ from traditional cancer therapies?
Genprex's therapies utilize gene delivery systems to target cancer cells more effectively, potentially revitalizing the body’s own ability to fight illness compared to traditional methods.
Where can investors find more information about Genprex?
Investors can find more information by visiting Genprex's official website, where they can also sign up for press releases and updates.
